Search Results for: metformin
-
Treatment of Type2 Diabetes
Hygieia Rewriting Advanced T2D Care!
We spoke with Eran Bashan, CEO, Co-founder, and Chairman of Hygieia based in Livonia, Michigan. See https://hygieia.com/ App is Small…
Read More » -
Treatment of Type2 Diabetes
Fine Tuning An A1C Strategy
The drug-specific and patient-specific factors described in our earlier coverage become a bit nuanced here.
Read More » -
Treatment of Type2 Diabetes
Which Combination Drug Therapy is Best for You?
Drug-specific and patient-specific factors determine the most appropriate drug therapies.
Read More » -
Treatment of Type2 Diabetes
2018 American Diabetes Association’s Practice Standards Recommend GLP-1 Injectables.
The benefits extend beyond glucose control to protecting cardiovascular health and helping some people lose weight.
Read More » -
Treatment of Type2 Diabetes
Aging Doesn’t Have To Mean Giving In On Quality
It’s crucial to stay engaged with your health care professionals and talk
Read More » -
Treatment of Type2 Diabetes
Good News About GLP-1 Drugs and Cardiovascular Health
A popular non-insulin injectable drug that long ago met the FDA cardiovascular safety test can now claim a cardiovascular benefit.
Read More » -
Treatment of Type2 Diabetes
Weighing the Benefits of a Bariatric Procedure
When diet and lifestyle changes to combat obesity don’t work, surgical approaches and new generation devices can, but they all…
Read More » -
Treatment of Type2 Diabetes
Janssen’s SGLT-2 Drugs and Risk of Amputations: What Happened, and What’s Next?
The European regulators have applied their amputation risk warning to all Janssen products in the SGLT-2 inhibitor class. But FDA…
Read More » -
Weight Loss
New CDC Diabetes Stats: Type 2 Still an Epidemic, But Rate of Growth Is Slowing
The CDC 2017 report on the prevalence of diabetes shows more Americans have diabetes or prediabetes than shown in the…
Read More » -
Treatment of Type2 Diabetes
FDA To Require Prominent Amputation Risk Warning for Canagliflozin SGLT-2 Inhibitors
Post-market clinical trials of the Type 2 medication canagliflozin to assess cardiovascular and renal risks have affirmed a suspected link…
Read More »
